Please login to the form below

Not currently logged in
Email:
Password:

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... For instance, we are exploring patient

  • Deal Watch July 2016 Deal Watch July 2016

    for the treatment of hyperkalaemia.

  • Deal Watch November 2015 Deal Watch November 2015

    Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,

  • Pharma deals during October 2013 Pharma deals during October 2013

    Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics